Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.

by Ping G Tepper, Jack Mardekian, Cristina Masseria, Hemant Phatak, Shital Kamble, Younos Abdulsattar, William Petkun, Gregory Y H Lip
Published 2018-01-01